Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (SPARe-1)
Satavaptan in the Prevention of Ascites Recurrence: a Double-blind, Randomised, Parallel-group Comparison of Satavaptan at 5 to 10 mg Daily Versus Placebo With Concomitant Diuretics in Patients With Recurrent Ascites Due to Cirrhosis of the Liver.
Sponsor: Sanofi
Terminated
This trial was terminated. No reason was provided.
A PHASE3 clinical study on Ascites and Liver Cirrhosis, this trial is terminated or withdrawn. The trial is conducted by Sanofi and has accumulated 8 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Belgrade, Serbia , Berlin, Germany , Bucharest, Romania , Budapest, Hungary , Diegem, Belgium , Guildford Surrey, United Kingdom , Kuala Lumpur, Malaysia , Laval, Canada , Macquarie Park, Australia and 14 more locations